Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis

An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow

Lutz, M. B., Kukutsch, N. A., Ogilvie, A. L. J., Rößner, S., Koch, F., Romani, N., & Schuler, G. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(98)00204-x · Cited by 2,972

Sample criteria for testing outlying observations

Grubbs, F. E. (1950) · The Annals of Mathematical Statistics · doi:10.1214/aoms/1177729885 · Cited by 1,631

IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge

Khader, S. A., Bell, G. K., Pearl, J. E., Fountain, J. J., Rangel‐Moreno, J., Cilley, G. E., Shen, F., Eaton, S. M., Gaffen, S. L., Swain, S. L., et al. (2007) · Nature Immunology · doi:10.1038/ni1449 · Cited by 1,468

Exploiting lymphatic transport and complement activation in nanoparticle vaccines

Reddy, S. T., van der Vlies, A. J., Simeoni, E., Angeli, V., Randolph, G. J., O’Neil, C. P., Lee, L. K., Swartz, M. A., & Hubbell, J. A. (2007) · Nature Biotechnology · doi:10.1038/nbt1332 · Cited by 1,355

Global tuberculosis control 2010

Behera, D. (2012) · The Indian Journal of Medical Research · Cited by 1,262

Induction and effector functions of TH17 cells

Bettelli, E., Korn, T., Oukka, M., & Kuchroo, V. K. (2008) · Nature · doi:10.1038/nature07036 · Cited by 1,243

The success and failure of BCG — implications for a novel tuberculosis vaccine

Andersen, P. L., & Doherty, T. M. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1211 · Cited by 791

Immune Control of Tuberculosis by IFN-γ-Inducible LRG-47

MacMicking, J. D., Taylor, G. A., & McKinney, J. D. (2003) · Science · doi:10.1126/science.1088063 · Cited by 685

Materials engineering for immunomodulation

Hubbell, J. A., Thomas, S. N., & Swartz, M. A. (2009) · Nature · doi:10.1038/nature08604 · Cited by 581

Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome

Sharp, F. A., Ruane, D., Claass, B., Creagh, E. M., Harris, J., Malyala, P., Singh, M., O’Hagan, D. T., Pétrilli, V., Tschopp, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804897106 · Cited by 536

From Sewer to Saviour—Targeting the Lymphatic System to Promote Drug Exposure and Activity

Trevaskis, N. L., Kaminskas, L. M., & Porter, C. J. H. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4608 · Cited by 654

Engineering synthetic vaccines using cues from natural immunity

Irvine, D. J., Swartz, M. A., & Szeto, G. L. (2013) · Nature Materials · doi:10.1038/nmat3775 · Cited by 605

Nanotechnology approaches for global infectious diseases

Kirtane, A. R., Verma, M., Karandikar, P., Furin, J., Langer, R., & Traverso, G. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00866-8 · Cited by 520

Nanoparticle Vaccines Against Infectious Diseases

Pati, R., Shevtsov, M. A., & Sonawane, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02224 · Cited by 521

Nanoparticle diffusion in respiratory mucus from humans without lung disease

Schuster, B. S., Suk, J. S., Woodworth, G. F., & Hanes, J. S. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.01.064 · Cited by 478

Nanotechnology for COVID-19: Therapeutics and Vaccine Research

Chauhan, G., Madou, M. J., Kalra, S., Chopra, V., Ghosh, D., & Martinez-Chapa, S. O. (2020) · ACS Nano · doi:10.1021/acsnano.0c04006 · Cited by 387

COVID-19 vaccines: The status and perspectives in delivery points of view

Chung, J. Y., Thone, M. N., & Kwon, Y. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.011 · Cited by 375

Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response

Thomas, S. N., Vokali, E., Lund, A. W., Hubbell, J. A., & Swartz, M. A. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.10.003 · Cited by 316

Immunological properties of gold nanoparticles

Dykman, L. A., & Khlebtsov, N. G. (2016) · Chemical Science · doi:10.1039/c6sc03631g · Cited by 267

Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose

de Titta, A., Ballester, M. C., Julier, Z., Nembrini, C., Jeanbart, L., van der Vlies, A. J., Swartz, M. A., & Hubbell, J. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313152110 · Cited by 254

Engineering Approaches to Immunotherapy

Swartz, M. A., Hirosue, S., & Hubbell, J. A. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003763 · Cited by 226

Generation of Effector Memory T Cell–Based Mucosal and Systemic Immunity with Pulmonary Nanoparticle Vaccination

Li, A. V., Moon, J. J., Abraham, W. D., Suh, H., Elkhader, J. A., Seidman, M. A., Yen, M., Im, E., Foley, M. H., Barouch, D. H., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006516 · Cited by 187

Polyfunctional CD4+ T Cells As Targets for Tuberculosis Vaccination

Lewinsohn, D. A., Lewinsohn, D. M., & Scriba, T. J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01262 · Cited by 176

New perspectives in nanomedicine

Thorley, A. J., & Tetley, T. D. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.06.008 · Cited by 180

Biomaterial Strategies for Immunomodulation

Hotaling, N. A., Tang, L., Irvine, D. J., & Babensee, J. E. (2015) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071813-104814 · Cited by 175

Applications of nanomaterials as vaccine adjuvants

Zhu, M., Wang, R., & Nie, G. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.29589 · Cited by 165

Mucosal Immunization with a pH-Responsive Nanoparticle Vaccine Induces Protective CD8 + Lung-Resident Memory T Cells

Knight, F. C., Gilchuk, P., Kumar, A., Becker, K. W., Sevimli, S., Jacobson, M. E., Suryadevara, N., Wang-Bishop, L., Boyd, K. L., Crowe, J. E., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b00326 · Cited by 133

Peripherally Administered Nanoparticles Target Monocytic Myeloid Cells, Secondary Lymphoid Organs and Tumors in Mice

Kourtis, I. C., Hirosue, S., de Titta, A., Kontos, S., Stegmann, T., Hubbell, J. A., & Swartz, M. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061646 · Cited by 129

Synthetic nanovaccines for immunotherapy

Luo, M., Samandi, L. Z., Wang, Z., Chen, Z. J., & Gao, J. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.033 · Cited by 126

Tunable T cell immunity towards a protein antigen using polymersomes vs. solid-core nanoparticles

Stano, A., Scott, E. A., Dane, K. Y., Swartz, M. A., & Hubbell, J. A. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.02.024 · Cited by 119

Advances and Opportunities in Nanoparticle‐ and Nanomaterial‐Based Vaccines against Bacterial Infections

Lin, L. C. W., Chattopadhyay, S., Lin, J., & Hu, C. J. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701395 · Cited by 109

Nanocarriers Targeting Dendritic Cells for Pulmonary Vaccine Delivery

Kunda, N. K., Somavarapu, S., Gordon, S. B., Hutcheon, G. A., & Saleem, I. Y. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0891-5 · Cited by 98

Implications of Lymphatic Transport to Lymph Nodes in Immunity and Immunotherapy

Thomas, S. N., Rohner, N. A., & Edwards, E. E. (2016) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-101515-014413 · Cited by 87

Nanoparticle size influences the magnitude and quality of mucosal immune responses after intranasal immunization

Stano, A., Nembrini, C., Swartz, M. A., Hubbell, J. A., & Simeoni, E. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.10.050 · Cited by 84

Nanotechnology Against The Novel Coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2): Diagnosis, Treatment, Therapy and Future Perspectives

Rashidzadeh, H., Danafar, H., Rahimi, H., Mozafari, F., Salehiabar, M., Rahmati, M.-A., Rahamouz-Haghighi, S., Mousazadeh, N., Mohammadi, A., Ertaş, Y. N., et al. (2021) · Nanomedicine · doi:10.2217/nnm-2020-0441 · Cited by 77

Simple nanoliposomes encapsulating Lycium barbarum polysaccharides as adjuvants improve humoral and cellular immunity in mice

Bo, R., Sun, Y., Zhou, S., Ou, N., Gu, P., Liu, Z., Hu, Y., Liu, J., & Wang, D. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s136820 · Cited by 72

Design of nanomaterial based systems for novel vaccine development

Liu, Y., Li, W., Kirberger, M., Liao, W., & Ren, J. (2016) · Biomaterials Science · doi:10.1039/c5bm00507h · Cited by 71

How can nanoparticles contribute to antituberculosis therapy?

Costa-Gouveia, J., Aínsa, J. A., Brodin, P. M., & Lucía, A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.011 · Cited by 68

Devices and formulations for pulmonary vaccination

Tonnis, W. F., Lexmond, A. J., Frijlink, H. W., de Boer, A. H., & Hinrichs, W. L. J. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.810622 · Cited by 66

Airway delivery of peptides and proteins using nanoparticles

Dombu, C. Y., & Betbeder, D. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.08.070 · Cited by 64

Potent Lymphatic Translocation and Spatial Control Over Innate Immune Activation by Polymer–Lipid Amphiphile Conjugates of Small‐Molecule TLR7/8 Agonists

Vrieze, J. D., Louage, B., Deswarte, K., Zhong, Z., Coen, R. D., Herck, S. V., Nuhn, L., Frich, C. K., Zelikin, A. N., Lienenklaus, S., et al. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201905687 · Cited by 64

Biomaterial strategies for generating therapeutic immune responses

Kelly, S. H., Shores, L. S., Votaw, N. L., & Collier, J. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.009 · Cited by 64

Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates

Agger, E. M. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.11.012 · Cited by 60

Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges

Stylianou, E., Paul, M. J., Reljić, R., & McShane, H. (2019) · Expert Review of Vaccines · doi:10.1080/14760584.2019.1692657 · Cited by 59

The expanding role of aerosols in systemic drug delivery, gene therapy and vaccination: an update

Laube, B. L. (2014) · Translational Respiratory Medicine · doi:10.1186/2213-0802-2-3 · Cited by 58

Vaccine nanocarriers: Coupling intracellular pathways and cellular biodistribution to control CD4 vs CD8 T cell responses

Rincón-Restrepo, M., Mayer, A. T., Hauert, S., Bonner, D. K., Phelps, E. A., Hubbell, J. A., Swartz, M. A., & Hirosue, S. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.03.047 · Cited by 55

Mucosal immunization with PspA (Pneumococcal surface protein A)-adsorbed nanoparticles targeting the lungs for protection against pneumococcal infection

Rodrigues, T. C., Oliveira, M. L. S., Schanoski, A. S., Rico, S. L. C., Poschinger-Figueiredo, D., Gonçalves, V. M., Ferreira, D. M., Kunda, N. K., Saleem, I. Y., & Miyaji, E. N. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191692 · Cited by 54

Pulmonary Vaccine Delivery: A Realistic Approach?

Tonnis, W. F., Kersten, G. F. A., Frijlink, H. W., Hinrichs, W. L. J., de Boer, A. H., & Amorij, J. (2012) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2011.0931 · Cited by 54

Nanoparticle conjugation enhances the immunomodulatory effects of intranasally delivered CpG in house dust mite-allergic mice

Ballester, M. C., Jeanbart, L., de Titta, A., Nembrini, C., Marsland, B. J., Hubbell, J. A., & Swartz, M. A. (2015) · Scientific Reports · doi:10.1038/srep14274 · Cited by 49

A high-throughput nanoimmunoassay chip applied to large-scale vaccine adjuvant screening

Garcia-Cordero, J. L., Nembrini, C., Stano, A., Hubbell, J. A., & Maerkl, S. J. (2013) · Integrative Biology · doi:10.1039/c3ib20263a · Cited by 48

Aerosol pulmonary immune engineering

Sudduth, E. R., Trautmann-Rodriguez, M., Gill, N. A., Bomb, K., & Fromen, C. A. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114831 · Cited by 51

Carrier molecules for use in veterinary vaccines

Gerdts, V., Mutwiri, G., Richards, J. M., den Hurk, S. V. D. L., & Potter, A. A. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.11.067 · Cited by 44

Targeted immunomodulation using antigen‐conjugated nanoparticles

McCarthy, D. P., Hunter, Z. N., Chackerian, B., Shea, L. D., & Miller, S. D. (2014) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1263 · Cited by 45

Roles of Mucosal Immunity againstMycobacterium tuberculosisInfection

Li, W., Deng, G., Li, M., Liu, X., & Wang, Y. (2012) · Tuberculosis Research and Treatment · doi:10.1155/2012/791728 · Cited by 44

Nanomaterials in the Prevention, Diagnosis, and Treatment of Mycobacterium Tuberculosis Infections

Xu, K., Liang, Z. C., Ding, X., Hu, H., Liu, S., Nurmik, M., Bi, S., Hu, F.-S., Ji, Z., Ren, J., et al. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201700509 · Cited by 44

Polymer micelles with pyridyl disulfide-coupled antigen travel through lymphatics and show enhanced cellular responses following immunization

Eby, J. K., Dane, K. Y., O’Neil, C. P., Hirosue, S., Swartz, M. A., & Hubbell, J. A. (2012) · Acta Biomaterialia · doi:10.1016/j.actbio.2012.06.007 · Cited by 40

Robust mucosal and systemic responses against HTLV-1 by delivery of multi-epitope vaccine in PLGA nanoparticles

Kabiri, M., Sankian, M., Sadri, K., & Tafaghodi, M. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.11.003 · Cited by 38

Nanoparticle Conjugation of Human Papillomavirus 16 E7-long Peptides Enhances Therapeutic Vaccine Efficacy against Solid Tumors in Mice

Galliverti, G., Tichet, M., Domingos‐Pereira, S., Hauert, S., Nardelli‐Haefliger, D., Swartz, M. A., Hanahan, D., & Wullschleger, S. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0166 · Cited by 36

A recombinant adenovirus expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis elicits strong antigen-specific immune responses in mice

Li, W., Deng, G., Li, M., Jin, Z., Zhao, L., Liu, X., & Wang, Y. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.06.007 · Cited by 35

Nebulized oil-in-water nanoemulsion mists for pulmonary delivery: development, physico-chemical characterization andin vitroevaluation

Nesamony, J., Shah, I. S., Kalra, A. V., & Jung, R. (2013) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2013.814065 · Cited by 35

Nanoscale Peptide Self-assemblies Boost BCG-primed Cellular Immunity Against Mycobacterium tuberculosis

Chesson, C. B., Huante, M. B., Nusbaum, R. J., Walker, A. G., Clover, T. M., Jagannath, C., Endsley, J. J., & Rudra, J. S. (2018) · Scientific Reports · doi:10.1038/s41598-018-31089-y · Cited by 35

Intrapulmonary Delivery of CpG Microparticles Eliminates Lung Tumors

Sato, T., Shimosato, T., Ueda, A., Ishigatsubo, Y., & Klinman, D. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0401 · Cited by 28

Decreased IL-17 during treatment of sputum smear-positive pulmonary tuberculosis due to increased regulatory T cells and IL-10

Xu, L., Cui, G., Jia, H., Zhu, Y., Ding, Y., Chen, J., Lu, C., Ye, P., Gao, H., Li, L., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0909-6 · Cited by 35

Mucosal Vaccines: Where Do We Stand?

Kraehenbühl, J.-P., & Neutra, M. R. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113136660186 · Cited by 35

HBHA vaccination may require both Th1 and Th17 immune responses to protect mice against tuberculosis

Verwaerde, C., Debrie, A., Dombu, C. Y., Legrand, D., Raze, D., Lecher, S., Betbeder, D., & Locht, C. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.09.024 · Cited by 32

Mycobacterium Tuberculosis and Interactions with the Host Immune System: Opportunities for Nanoparticle Based Immunotherapeutics and Vaccines

Bekale, R. B., du Plessis, S., Hsu, N., Sharma, J. R., Sampson, S. L., Jacobs, M., Meyer, M., Morse, G. D., & Dube, A. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2528-9 · Cited by 32

Targeting the deep lungs, Poloxamer 407 and a CpG oligonucleotide optimize immune responses to Mycobacterium tuberculosis antigen 85A following pulmonary delivery

Todoroff, J., Učakar, B., Inglese, M., Vandermarliere, S., Fillée, C., Renauld, J., Huygen, K., & Rita Vanbever, A. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.11.020 · Cited by 31

Potential of nanotechnology as a delivery platform against tuberculosis: Current research review

Choudhary, S., & Devi, V. K. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.01.035 · Cited by 28

Epitope‐specific CD4+, but not CD8+, T‐cell responses induced by recombinant influenza A viruses protect against Mycobacterium tuberculosis infection

Flórido, M., Pillay, R., Gillis, C. M., Xia, Y., Turner, S. J., Triccas, J. A., Stambas, J., & Britton, W. J. (2014) · European Journal of Immunology · doi:10.1002/eji.201444954 · Cited by 28

Potential of polymeric particles as future vaccine delivery systems/adjuvants for parenteral and non-parenteral immunization against tuberculosis: A systematic review.

Khademi, F., Derakhshan, M., Avarvand, A. Y., & Tafaghodi, M. (2018) · Europe PMC (PubMed Central) · doi:10.22038/ijbms.2017.22059.5648 · Cited by 28

Nanoparticle-Conjugated Toll-Like Receptor 9 Agonists Improve the Potency, Durability, and Breadth of COVID-19 Vaccines

Ou, B. S., Baillet, J., Picece, V. C. T. M., Gale, E. C., Powell, A. E., Saouaf, O. M., Yan, J., Nejatfard, A., Hernandez, H. L., & Appel, E. A. (2024) · ACS Nano · doi:10.1021/acsnano.3c09700 · Cited by 27

Mesoporous Silica Nanoparticles as a Potential Platform for Vaccine Development against Tuberculosis

Montalvo-Quirós, S., Vallet‐Regí, M., Palacios, A., Anguíta, J., Prados‐Rosales, R., González, B., & Luque-Garcia, J. L. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121218 · Cited by 24

Engineering Vaccines for Tissue‐Resident Memory T Cells

Knight, F. C., & Wilson, J. T. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000230 · Cited by 24

Development of novel carrier(s) mediated tuberculosis vaccine: More than a tour de force

Garg, N. K., Dwivedi, P., Jain, A., Tyagi, S., Sahu, T., & Tyagi, R. K. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.05.028 · Cited by 23

Recombinant Ag85B vaccine by taking advantage of characteristics of human parainfluenza type 2 virus vector showed Mycobacteria-specific immune responses by intranasal immunization

Watanabe, K., Matsubara, A., Kawano, M., Mizuno, S., Okamura, T., Tsujimura, Y., Inada, H., Nosaka, T., Matsuo, K., & Yasutomi, Y. (2014) · Vaccine · doi:10.1016/j.vaccine.2013.11.108 · Cited by 22

Selective drug deposition in lungs through pulmonary drug delivery system for effective management of drug-resistant TB

Sankhe, K., Khan, T., Bhavsar, C., Momin, M., & Omri, A. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1609937 · Cited by 18

Nanotoxoids: Biomimetic Nanoparticle Vaccines against Infections

Guo, Z., Kubiatowicz, L. J., Fang, R. H., & Zhang, L. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100072 · Cited by 22

A Cationic Micelle Complex Improves CD8+ T Cell Responses in Vaccination Against Unmodified Protein Antigen

Brubaker, C. E., Panagiotou, V., Demurtas, D., Bonner, D. K., Swartz, M. A., & Hubbell, J. A. (2015) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5b00456 · Cited by 20

Advancements in Nanoparticle-Based Adjuvants for Enhanced Tuberculosis Vaccination: A Review

Wang, J., Zhao, Z., Wang, Q., Shi, J., Wong, D. W., & Cheung, J. C. (2024) · Vaccines · doi:10.3390/vaccines12121335 · Cited by 19

Nanocarriers for Respiratory Diseases Treatment: Recent Advances and Current Challenges

Trapani, A., Gioia, S. D., Castellani, S., Carbone, A., Cavallaro, G., Trapani, G., & Conese, M. (2014) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026614666140329225817 · Cited by 19

Advanced Nanosystems and Emerging Therapies: Innovations in Tuberculosis Treatment and Drug Resistance

Sharma, A., Sharma, V., Sharma, S., Sharma, S., Sharma, M., & Sivanesan, I. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17111459 · Cited by 16

Comparative efficacy analysis of anti-microbial peptides, LL-37 and indolicidin upon conjugation with CNT, in human monocytes

Pradhan, B., Guha, D., Murmu, K. C., Sur, A., Ray, P., Das, D., & Aich, P. (2017) · Journal of Nanobiotechnology · doi:10.1186/s12951-017-0278-1 · Cited by 16

Current advancements in nanoparticles for vaccines and drug delivery for the treatment of tuberculosis

Sharma, D. K. (2025) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2025.107138 · Cited by 15

Advancing Immunotherapeutic Vaccine Strategies Against Pulmonary Tuberculosis

Afkhami, S., Villela, A. D., D’Agostino, M. R., Jeyanathan, M., Gillgrass, A. E., & Xing, Z. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.557809 · Cited by 15

Vaccination with mycobacterial lipid loaded nanoparticle leads to lipid antigen persistence and memory differentiation of antigen-specific T cells

Morgun, E., Zhu, J. Y., Almunif, S., Bobbala, S. K. R., Aguilar, M. S., Wang, J., Conner, K., Cui, Y., Cao, L., Seshadri, C., et al. (2023) · eLife · doi:10.7554/elife.87431 · Cited by 16

In vivo imaging of T cells loaded with gold nanoparticles: a pilot study

Li, H., Diaz, L., Lee, D. Y., Cui, L., Liang, X., & Cheng, Y. (2013) · La radiologia medica · doi:10.1007/s11547-013-0335-2 · Cited by 14

Strategy to Enhance Dendritic Cell‐Mediated DNA Vaccination in the Lung

Kim, Y. C., Hsueh, H. T., Kim, N., Rodriguez, J., Leo, K. T., Rao, D., West, N. E., Hanes, J. S., & Suk, J. S. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000228 · Cited by 12

A comprehensive review on efficient approaches for combating coronaviruses

Pouresmaieli, M., Ekrami, E., Akbari, A., Noorbakhsh, N., Moghadam, N. B., & Mamoudifard, M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112353 · Cited by 12

Development of a New Tuberculosis Vaccine: Is there Value in the Mucosal Approach?

Diogo, G. R., & Reljić, R. (2014) · Immunotherapy · doi:10.2217/imt.14.62 · Cited by 11

Nasal mRNA Nanovaccine with Key Activators of Dendritic and MAIT Cells for Effective Against Lung Tumor Metastasis in Mice Model

Li, A., Cai, X., Li, D., Yu, Y., Liu, C., Shen, J., You, J., Qiao, J., & Wang, F. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s479741 · Cited by 10

Transgene Delivery to Human Induced Pluripotent Stem Cells Using Nanoparticles

Yamoah, M., Thai, P. N., & Zhang, X.-D. (2021) · Pharmaceuticals · doi:10.3390/ph14040334 · Cited by 10

Strategy to Enhance Dendritic Cell‐Mediated DNA Vaccination in the Lung

Kim, Y. C., Hsueh, H. T., Kim, N., Rodriguez, J., Leo, K. T., Rao, D., West, N. E., Hanes, J. S., & Suk, J. S. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000013 · Cited by 9

CNA-loaded PLGA nanoparticles improve humoral response againstS. aureus-mediated infections in a mouse model: subcutaneous vs. nasal administration strategy

Genta, I., Colonna, C., Conti, B., Caliceti, P., Salmaso, S., Speziale, P., Pietrocola, G., Chiesa, E., Modena, T., & Dorati, R. (2016) · Journal of Microencapsulation · doi:10.1080/02652048.2016.1260661 · Cited by 9

Novel Nanotechnology Based Delivery Systems for Chemotherapy and Prophylaxis of Tuberculosis

Jain, R., Savla, H. M., Naik, I., Maniar, J., Punjabi, K., Vaidya, S. P., & Menon, M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813351-4.00034-1 · Cited by 9

Correlates of Protection from Tuberculosis

Álvarez, M. P. P., Marshall, J. L., & Tanner, R. (2023) · Springer eBooks · doi:10.1007/978-3-031-24355-4_6 · Cited by 10

Gold nanoparticle-based strategies against SARS-CoV-2: A review

Rasmi, Y., Kırboğa, K. K., Khan, J., Gupta, E., Attia, F. M., Yallapu, M. M., & Pilaquinga, F. (2023) · REVIEWS ON ADVANCED MATERIALS SCIENCE · doi:10.1515/rams-2023-0105 · Cited by 8

Tuberculosis vaccine developments and efficient delivery systems: A comprehensive appraisal

Hosseinpour, R., Hasani, A., Baradaran, B., Abdolalizadeh, J., Salehi, R., Hasani, A., Nabizadeh, E., Yekani, M., Hasani, R., Kafil, H. S., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26193 · Cited by 8

Development of Adjuvanted Solid Fat Nanoemulsions for Pulmonary Hepatitis B Vaccination

Minz, S., & Pandey, R. S. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.02.007 · Cited by 7

Considerations for the Human Health Implications of Nanotheranostics

Burgum, M. J., Evans, S. J., Jenkins, G. J. S., Doak, S. H., & Clift, M. J. D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813339-2.00010-4 · Cited by 6

Nanoparticle Vaccines Against Infectious Diseases

(2020) · Frontiers research topics · doi:10.3389/978-2-88963-327-2 · Cited by 6

Pulmonary Administration of Subunit Vaccines

Tonnis, W. F., Huckriede, A. L. W., Hinrichs, W. L. J., & Frijlink, H. W. (2014) · Advances in delivery science and technology · doi:10.1007/978-1-4939-1417-3_16 · Cited by 5

Amphiphile Polymer‐Lipidkonjugate zur potenten lymphatischen Anreicherung von TLR7/8‐Agonisten ermöglichen eine örtlich begrenzte Aktivierung des angeborenen Immunsystems

Vrieze, J. D., Louage, B., Deswarte, K., Zhong, Z., Coen, R. D., Herck, S. V., Nuhn, L., Frich, C. K., Zelikin, A. N., Lienenklaus, S., et al. (2019) · Angewandte Chemie · doi:10.1002/ange.201905687 · Cited by 5

Intranasal delivery of nanoparticle-based vaccine increases protection against S. pneumoniae

Mott, B., Thamake, S. I., Vishwanatha, J. K., & Jones, H. P. (2013) · Journal of Nanoparticle Research · doi:10.1007/s11051-013-1646-x · Cited by 5

Reactivation of immune responses against Mycobacterium tuberculosis by boosting with the CpG oligomer in aged mice primarily vaccinated with Mycobacterium bovis BCG

Taniguchi, K., Takii, T., Yamamoto, S., Maeyama, J., Iho, S., Maruyama, M., Iizuka, N., Ozeki, Y., Matsumoto, S., Hasegawa, T., et al. (2013) · Immunity & Ageing · doi:10.1186/1742-4933-10-25 · Cited by 5

Goals and strategies in vaccine development against tuberculosis

Konjengbam, B. D., Meitei, H. N., Pandey, A., & Haobam, R. (2025) · Molecular Immunology · doi:10.1016/j.molimm.2025.04.016 · Cited by 4

Pulmonary Delivery of Biopharmaceuticals

Andrade, F., Moura, C. C., & Sarmento, B. F. C. C. (2014) · Springer eBooks · doi:10.1007/978-1-4614-9524-6_7 · Cited by 4

Nanomedicine at the Pulmonary Frontier: Immune-Centric Approaches for Respiratory Disease Treatment

Kaur, J. K., Sharma, A., Passi, G., Dey, P., Khajuria, A., Alajangi, H. K., Jaiswal, P. K., Barnwal, R. P., & Singh, G. (2024) · Immunological Investigations · doi:10.1080/08820139.2023.2298398 · Cited by 3

Nanotechnology laying new foundations for combating COVID-19 pandemic

Jain, S., Hussain, A., Bhatt, A., Nasa, A., Navani, N. K., & Mutreja, R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90538-1.00019-4 · Cited by 3

Novel vaccination strategies and approaches against human tuberculosis

Méndez‐Samperio, P. (2019) · Scandinavian Journal of Immunology · doi:10.1111/sji.12774 · Cited by 3

Vaccine Preparation

Price, D. N., Kunda, N. K., McBride, A. A., & Muttil, P. (2016) · doi:10.1002/9781118943182.ch4 · Cited by 3

Mucosal delivery of antigen‐coated nanoparticles to lungs confers protective immunity against tuberculosis infection in mice

Stylianou, E., Diogo, G. R., Pepponi, I., van Dolleweerd, C. J., Arias, M. A., Locht, C., Rider, C. C., Sibley, L. S., Cutting, S. M., Loxley, A., et al. (2013) · European Journal of Immunology · doi:10.1002/eji.201343887 · Cited by 42

A novel nanoparticle vaccine displaying multistage tuberculosis antigens confers protection in mice infected with H37Rv

Ding, Y., Li, Y., Wu, Z., Zhou, Y., Guo, Y., Tian, S. I. P., Yu, R., Deng, C., Wei, R., Chen, H., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01216-8 · Cited by 16

Single-dose Ag85B-ESAT-6 loaded–poly(lactic-co-glycolic acid) nanoparticles confer protective immunity against tuberculosis

Malik, A., Gupta, M. K., Mani, R., & Bhatnagar, R. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s172391 · Cited by 39

Evaluation of PLGA, lipid-PLGA hybrid nanoparticles, and cationic pH-sensitive liposomes as tuberculosis vaccine delivery systems in a Mycobacterium tuberculosis challenge mouse model – A comparison

Szachniewicz, M. M., Neustrup, M. A., van den Eeden, S. J. F., van Meijgaarden, K. E., Franken, K. L. M. C., van Veen, S., Koning, R. I., Limpens, R. W. A. L., Geluk, A., Bouwstra, J. A., et al. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124842 · Cited by 4

Evaluation of adjuvants for a pulmonary vaccine against tuberculosis

Todoroff, J. (2013) · Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B))